USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
SANERON CCEL THERAPEUTICS, INC.
Address:
3802 Spectrum Blvd.
TAMPA, FL 33612-
Phone:
N/A
URL:
N/A
EIN:
111328511
DUNS:
39606491
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $150,000.00 1
STTR Phase I $1,713,943.00 10
STTR Phase II $2,608,663.00 1

Award List:

Neural Stem Cells From Umbilical Cord Blood

Award Year / Program / Phase:
2001 / STTR / Phase I
Award Amount:
$107,000.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF SOUTH FLORIDA
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): A neural stem cell is a single cell with the ability to proliferate, to self-renew over the lifetime of the organism, to generate a large number of clonally-related progeny and to replace limited numbers of neural cells in the adult brain.… More

Sertoli Cell-Treated Umbilical Cord Blood for Stroke

Award Year / Program / Phase:
2003 / STTR / Phase I
Award Amount:
$133,060.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF SOUTH FLORIDA
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): With the recent observations that stem-like cells outside the central nervous system (CNS) can differentiate into neurons, it is no longer inconceivable to suggest that stem cells derived from human umbilical cord blood (hUCB) could be used for cellular… More

Sertoli Treated Cord Blood for Spinal Cord Injury

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$150,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Stem cells from human umbilical cord blood (hUCB) represent a promising cellular therapeutic strategy for the treatment of cord injury (SCI). These cells are capable of differentiating into neurons and glia in vivo, engraft into specific sites of neurological… More

Cord Blood: Treatment for Acute Myocardial Infarction

Award Year / Program / Phase:
2005 / STTR / Phase I
Award Amount:
$184,249.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF SOUTH FLORIDA
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Transplantation of human umbilical cord stem cells (hUCBC) has been shown to be effective in limiting infarct size and in the preservation of left ventricular function and anatomy in a rat model. These effects have been present in studies both utilizing and not… More

HUCBC modulation of Alzheimer-like pathology and behavioral changes

Award Year / Program / Phase:
2007 / STTR / Phase I
Award Amount:
$140,383.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF SOUTH FLORIDA
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Modulation of the inflammatory cascade by several diverse strategies including A immunization, non-steroidal anti-inflammatory drug (NSAID) administration, and manipulation of microglial activation states have all been shown to reduce Alzheimer disease (AD)-like… More

Transplantation of Umbilical Cord Blood Stem Cells in Ischemic Brain Injury

Award Year / Program / Phase:
2008 / STTR / Phase I
Award Amount:
$96,315.00
Agency:
HHS
Principal Investigator:
Research Institution:
N/A
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Human umbilical cord blood is a rich source of hematopoietic stem cells that can be used to re-populate the blood and immune systems. In preliminary studies we have identified a novel population of non-hematopoietic cel ls that exhibit extensive self-renewal and… More

Neuroprotective therapy of stroke with HUCNC and simvastatin

Award Year / Program / Phase:
2010 / STTR / Phase I
Award Amount:
$176,926.00
Agency:
HHS
Principal Investigator:
Jieli Chen – 313-916-1991
Research Institution:
Henry Ford Health System
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): There is a compelling need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke. Human umbilical cord blood cells (HUCBCs) treatment dose-dependently improves functional outcome after stroke. UCBCs are associated… More

HUCBC modulation of Alzheimer's-like pathology and behavioral changes

Award Year / Program / Phase:
2010 / STTR / Phase II
Award Amount:
$2,608,663.00
Agency:
HHS
Principal Investigator:
Jun Tan – 813-974-3985
Research Institution:
University Of South Florida
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral… More

Neurorestorative therapy of stroke with HUCBC in T2DM rats

Award Year / Program / Phase:
2013 / STTR / Phase I
Award Amount:
$422,946.00
Agency:
HHS
Principal Investigator:
Jieli Chen – 313-916-1991
Research Institution:
HENRY FORD HEALTH SYSTEM
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with… More